BRTX
BioRestorative Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.15
+2.99%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
Market Cap
$4.09M
MomentumView details →
1D Return
+2.99%
YTD Return
−87.60%
RSI (14)
23.4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.0x
Market Cap
$4.09M
RSI (14)
23.4
MomentumView details →
1D Return
+2.99%
YTD Return
−87.60%
SummaryUpdated Mar 1, 2026
BioRestorative Therapies, Inc. (OTCQB:BRTX) is a life sciences company founded in 1997 and based in Melville, New York, that focuses on developing regenerative medicine products using adult stem cell therapies. Originally incorporated as Stem Cell Assurance, Inc., the company changed its name to BioRestorative Therapies in August 2011 and went public in December 2012. The company operates two primary therapeutic programs: a disc/spine treatment program called brtxDisc and a metabolic disorders program called ThermoStem, both utilizing different types of stem cell technologies to address unmet medical needs.
Similar companies
Latest newsMore news →
BioRestorative Therapies' board approved a 1-for-20 reverse stock split of its common stock, effective September 7, 2026, to regain Nasdaq compliance with the $1.00 minimum bid price requirement.2d agoKatharyn Field resigned as Interim Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and Board member of BioRestorative Therapies, effective late August 2026, with successors appointed.3d ago